|Imperial Innovations||Managing Director||United Kingdom|
How to keep the founding scientists committed?
Tony Hickson BSc, MBA, CLP, RTTP is the Managing Director of Technology Transfer, Imperial Innovations Ltd and an Executive Director on the board of Touchstone Innovations Group PLC, an early stage investor in high technology start-ups with over £0.5bn of investment funding raised to date. At Imperial Innovations, Tony is responsible for the team providing intellectual property sourcing, licensing and spin-out support & incubation services to Imperial College London. Prior to joining the company in 2002, Tony had acquired 15 years of commercial and business development experience in bioscience companies including Wellcome Group, Murex Biotech, Abbott Laboratories and Kalibrant Limited. He has been a board director or observer for a number of start-up companies including Emcision, Polytherics (now Abzena) and Catapult Therapy TCR Limited (recently exited), and was instrumental in the creation of companies such as Thiakis (sold to Wyeth, now Pfizer, in 2008), Respivert (sold to J&J in 2010), Circassia (floated on LSE in 2014) and Cell Medica (in advanced clinical studies). Tony is a Certified Licensing Professional, a board director of PraxisUnico and has acted as Chairman of the Intellectual Property Boards of two European Institute of Technology KICs (EIT Health and Climate KIC).